REGENXBIO, Inc. (RGNX)
9.70
+0.38
(+4.08%)
USD |
NASDAQ |
Sep 02, 09:46
REGENXBIO Cash and Short Term Investments (Quarterly) : 105.74M for June 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 105.74M |
| March 31, 2026 | 150.49M |
| December 31, 2025 | 230.07M |
| September 30, 2025 | 274.20M |
| June 30, 2025 | 323.30M |
| March 31, 2025 | 267.87M |
| December 31, 2024 | 234.69M |
| September 30, 2024 | 255.46M |
| June 30, 2024 | 290.36M |
| March 31, 2024 | 338.70M |
| December 31, 2023 | 275.26M |
| September 30, 2023 | 301.89M |
| June 30, 2023 | 320.08M |
| March 31, 2023 | 331.82M |
| December 31, 2022 | 364.64M |
| September 30, 2022 | 382.42M |
| June 30, 2022 | 402.96M |
| March 31, 2022 | 394.13M |
| December 31, 2021 | 457.44M |
| September 30, 2021 | 339.86M |
| June 30, 2021 | 374.74M |
| March 31, 2021 | 440.88M |
| December 31, 2020 | 475.74M |
| Date | Value |
|---|---|
| September 30, 2020 | 241.52M |
| June 30, 2020 | 269.19M |
| March 31, 2020 | 279.26M |
| December 31, 2019 | 296.21M |
| September 30, 2019 | 331.72M |
| June 30, 2019 | 341.50M |
| March 31, 2019 | 285.22M |
| December 31, 2018 | 319.76M |
| September 30, 2018 | 372.59M |
| June 30, 2018 | 286.49M |
| March 31, 2018 | 229.87M |
| December 31, 2017 | 160.78M |
| September 30, 2017 | 166.66M |
| June 30, 2017 | 162.08M |
| March 31, 2017 | 145.81M |
| December 31, 2016 | 89.55M |
| September 30, 2016 | 91.77M |
| June 30, 2016 | 94.21M |
| March 31, 2016 | 101.06M |
| December 31, 2015 | 114.14M |
| September 30, 2015 | 213.35M |
| June 30, 2015 | 85.22M |
| March 31, 2015 | 25.37M |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| AbbVie, Inc. | 6.569B |
| Capricor Therapeutics, Inc. | 237.93M |
| Biogen, Inc. | 1.285B |
| United Therapeutics Corp. | 2.662B |
| Ardelyx, Inc. | 281.83M |